Fungal Infections and New Biologic Therapies

Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis

(2016) Fabrizio Cantini et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Histoplasmosis-Associated Hospitalizations in the United States, 2001–2012

(2016) Kaitlin Benedict et al.   Open Forum Infectious Diseases

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

(2015) R. F. van Vollenhoven et al.   JOURNAL OF RHEUMATOLOGY

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis

(2015) Parambir S. Dulai et al.   PHARMACOTHERAPY

Long-Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years

(2015) Daniel J. Lovell et al.   Arthritis & Rheumatology

PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases

(2015) Man Cai Wang et al.   MEDICINE

Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study

(2014) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)

(2014) Denis Poddubnyy et al.   ANNALS OF THE RHEUMATIC DISEASES

Biologic Therapies in Rheumatoid Arthritis and the Risk of Opportunistic Infections: A Meta-analysis

(2014) Irene S. Kourbeti et al.   CLINICAL INFECTIOUS DISEASES

Beyond Tumor Necrosis Factor Inhibition: The Expanding Pipeline of Biologic Therapies for Inflammatory Diseases and Their Associated Infectious Sequelae

(2014) S. A. Novosad et al.   CLINICAL INFECTIOUS DISEASES

Longterm Safety, Efficacy, and Inhibition of Structural Damage Progression Over 5 Years of Treatment with Abatacept in Patients with Rheumatoid Arthritis in the Abatacept in Inadequate Responders to Methotrexate Trial

(2014) J. M. Kremer et al.   JOURNAL OF RHEUMATOLOGY

Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab

(2014) Daisuke Hoshi et al.   Modern Rheumatology

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pneumocystis jirovecii Pneumonia in Patients Receiving Tumor-Necrosis-Factor-Inhibitor Therapy: Implications for Chemoprophylaxis

(2014) James A. Grubbs et al.   Current Rheumatology Reports

Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment

(2014) Rieke Alten et al.   Arthritis & Rheumatology

Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials

(2013) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

(2013) Joel Kremer et al.   ANNALS OF INTERNAL MEDICINE

Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study

(2013) John W Baddley et al.   ANNALS OF THE RHEUMATIC DISEASES

Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials

(2013) V P Bykerk et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

(2013) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis

(2013) Jonathan Kay et al.   ANNALS OF THE RHEUMATIC DISEASES

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial

(2013) Michael Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Endemic Fungal Infections in Inflammatory Bowel Disease Associated with Anti-TNF Antibody Therapy

(2013) Miguel E. Ordonez et al.   INFLAMMATORY BOWEL DISEASES

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fungal Infections Complicating Tumor Necrosis Factor α Blockade Therapy

(2012) Sotirios Tsiodras et al.   MAYO CLINIC PROCEEDINGS

Pityriasis versicolor during anti-TNF-α monoclonal antibody therapy: therapeutic considerations

(2012) Riccardo Balestri et al.   MYCOSES

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs

(2012) Sara Taroumian et al.   ARTHRITIS CARE & RESEARCH

Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial

(2011) Maria W. Greenwald et al.   ARTHRITIS AND RHEUMATISM

Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009

(2011) Timothy C Olson et al.   BMC INFECTIOUS DISEASES

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

(2011) Kenneth B. Gordon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Integrated safety in tocilizumab clinical trials

(2011) Michael H Schiff et al.   ARTHRITIS RESEARCH & THERAPY

The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses

(2011) William G Dixon et al.   ARTHRITIS RESEARCH & THERAPY

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry

(2010) D. Salmon-Ceron et al.   ANNALS OF THE RHEUMATIC DISEASES

Dermatophytosis during anti-TNF-α monoclonal antibody therapy

(2010) Federico Bardazzi et al.   MYCOSES

Abatacept treatment for rheumatoid arthritis

(2010) M. Schiff   RHEUMATOLOGY

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

(2010) L. Campbell et al.   RHEUMATOLOGY

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

(2010) J. B. Galloway et al.   RHEUMATOLOGY

Recognition, Diagnosis, and Treatment of Histoplasmosis Complicating Tumor Necrosis Factor Blocker Therapy

(2009) Chadi A. Hage et al.   CLINICAL INFECTIOUS DISEASES

Invasive Fungal Infections in the Era of Biologics

(2009) Tamra M. Arnold et al.   CLINICS IN CHEST MEDICINE

Aspergillosis in patients treated with monoclonal antibodies

(2009) Wagner L. Nedel et al.   REVISTA IBEROAMERICANA DE MICOLOGIA

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

(2008) C Salliot et al.   ANNALS OF THE RHEUMATIC DISEASES

Mycobacterial and Other Serious Infections in Patients Receiving Anti–Tumor Necrosis Factor and Other Newly Approved Biologic Therapies: Case Finding through the Emerging Infections Network

(2008) Kevin L. Winthrop et al.   CLINICAL INFECTIOUS DISEASES

Clinical and Radiological Features of Pneumocystis Pneumonia in Patients with Rheumatoid Arthritis, in comparison with Methotrexate Pneumonitis and Pneumocystis Pneumonia in Acquired Immunodeficiency Syndrome: A Multicenter Study

(2008) Hitoshi Tokuda et al.   INTERNAL MEDICINE